ClinicalTrials.gg
Not yet recruitingNCT06878651Updated Mar 17, 2025

The Instant Effect of Whole Body Vibration in Diabetics

An interventional study of The Whole Body Vibration in Diabetus Mellitus, Diabetic Foot Ulcer and Diabetic Neuropathic Ulcer, sponsored by Hacettepe University. Not yet recruiting at 1 site in Turkey. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Hacettepe University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Diabetic Foot with a site in Turkey — 14 open to participants now, 18 under way, none of them phase 3. Diabetic Foot · Turkey.

Planned enrollment
34th of 39
40 · median 73
Started
2025
with 7 others
No phase
36 of 48
12 open now
Primary completion
2026-02
later than 11 of 17 live
Registered
35th of 48
by date
Lead sponsor
3 of 48
Hacettepe University

Among the 48 studies in Diabetic Foot with a site in Turkey, this one is the 34th largest by planned enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2025, is one of 36 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 35th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

14 of the 48 studies in Diabetic Foot with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Diabetic Foot with a site in Turkey, or all of them as a file.
02

Study summary

Overview of Diabetes and Its Complications:

  • Diabetes is a chronic health issue that can lead to various complications, affecting human health negatively. One of these complications is diabetic peripheral neuropathy (DPN), which results from hyperglycemia and affects peripheral nerves. This can lead to sensory loss, motor dysfunction, and ultimately, disability.
  • The complications from diabetes can result in the loss of function and disability, affecting various systems, including the nervous system (e.g., retinopathy, neuropathy, and atherosclerosis).

Peripheral Neuropathy in Diabetes:

  • DPN occurs due to damage to peripheral nerves caused by hyperglycemia. Over time, it affects the small unmyelinated fibers responsible for pain and temperature sensations, leading to axonal degeneration and demyelination, causing sensory loss.
  • In later stages, motor dysfunction can also occur, impacting intrinsic foot muscles, leading to muscle weakness and atrophy.

Whole Body Vibration (WBV) Therapy:

  • WBV is a therapeutic method that uses mechanical vibrations from a vibrating platform to stimulate muscle contractions. It is being researched for its effects on managing diabetic neuropathy and related complications.
  • Studies have shown that WBV can improve balance, functional independence, and postural stability in patients with diabetes, potentially serving as an alternative or complement to traditional balance exercises.
  • A randomized controlled trial compared the effects of WBV and Tai Chi on postural balance and found that WBV was more effective in promoting functional independence and balance.

Impact on Sensory Function and Balance:

  • As DPN progresses, sensory loss may prevent patients from noticing injuries, which could lead to severe complications. A study conducted in 2017 showed that WBV improved vibration perception thresholds (VPT) in patients with type 2 diabetes and peripheral neuropathy, indicating improved sensory function, which is crucial for maintaining balance and walking.
  • This improvement is thought to be linked to increased blood circulation in peripheral tissues and improved glucose levels due to WBV therapy.

Dual Task Performance and WBV:

  • Dual-task performance, which involves performing cognitive and motor tasks simultaneously, is typically impaired in patients with diabetic neuropathy, leading to difficulties in daily activities. WBV has shown potential in improving muscle strength and balance, which could enhance patients' ability to perform dual tasks more effectively.

Research Findings:

  • Several studies have demonstrated that WBV training can significantly improve both static and dynamic balance in patients with diabetic neuropathy. Given that balance issues are common in these patients and contribute to a higher risk of falls, these improvements are particularly important.
  • The literature emphasizes the need for continued research to clarify the physiological mechanisms behind WBV's effects on sensory feedback mechanisms, which are essential for postural control.

Need for Further Research:

  • Despite promising findings, some studies have pointed out the need for more research to validate the clinical efficacy of WBV for managing chronic complications like neuropathic pain and improving quality of life in diabetic patients.
  • There is a need for better-designed studies to confirm the long-term benefits of WBV training in diabetic patients and to develop standardized protocols for its use.

Proposed Study:

  • A planned study aims to investigate the immediate effects of WBV on balance, dual-task performance, and walking in individuals with type 2 diabetes and peripheral neuropathy. The study will include 40 patients who meet specific inclusion criteria, with participants randomized into two groups (WBV training group and control group).
  • Data will be collected on participants' balance performance (using the Timed Up and Go test), dual-task performance (using a dual-task cost formula), and walking features (using the 1-minute walk test). The results will be analyzed using SPSS software.

Methodology:

  • The study will use random assignment and include a control group to evaluate the immediate effects of WBV. Data collection will include assessments of balance, dual-task performance, and walking capabilities before and after WBV treatment.
Read the detailed description

Sure! Here's a more detailed and extended version of the summary:

Diabetes is a chronic health condition that can lead to various complications, affecting many aspects of human health. One of the significant complications resulting from diabetes is peripheral neuropathy, which is caused by hyperglycemia-induced damage to peripheral nerves. Over time, this condition results in axonal degeneration and demyelination, particularly affecting small unmyelinated fibers responsible for pain and temperature sensation, leading to sensory loss. In advanced stages, it can result in motor dysfunction, which particularly affects intrinsic foot muscles, leading to muscle weakness and atrophy. Peripheral neuropathy can significantly impair balance, dual-task performance, and gait, all of which are crucial for maintaining functional independence and mobility in diabetic patients.

The effect of Whole Body Vibration (WBV) training on these aspects has been an emerging research area. WBV, which uses mechanical vibrations produced by a vibrating platform to stimulate muscle contractions, has shown potential benefits in improving balance, dual-task performance, and gait in individuals with diabetic neuropathy. Several studies have suggested that WBV can serve as a complementary or superior alternative to traditional balance training exercises. For instance, a randomized controlled trial comparing WBV and Tai Chi in diabetic patients found that WBV was more effective than Tai Chi in promoting functional independence and improving balance.

In patients with diabetic peripheral neuropathy (DPN), sensory loss may prevent them from recognizing injuries, leading to severe complications. A study from 2017 explored the impact of WBV on vibration perception thresholds (VPT) in patients with type 2 diabetes and peripheral neuropathy, finding significant improvements in VPT, which indicated enhanced sensory function, critical for maintaining balance and gait. This improvement was attributed to increased blood circulation in peripheral tissues and better glucose control, which positively influenced sensory feedback mechanisms crucial for postural control.

Moreover, WBV has been shown to improve both static and dynamic balance in individuals with DPN, which is vital for reducing fall risks in these patients. The improvements in balance are believed to result from muscle contraction stimulation and the proprioceptive feedback provided by the vibrations. Furthermore, dual-task performance, which is often impaired in patients with DPN due to the difficulty of performing cognitive and motor tasks simultaneously, might also improve with WBV. This improvement could help patients perform better in daily activities that require multitasking, such as walking while engaging in cognitive tasks.

In the existing literature, there is evidence that WBV training enhances balance and walking ability in diabetic patients, although there is a gap in research that simultaneously addresses balance, dual-task performance, and gait parameters in type 2 diabetes patients. A systematic review conducted by Robinson and colleagues in 2018 noted the potential benefits of WBV in managing neuropathic pain and improving the quality of life for DPN patients, although the clinical effectiveness of WBV as an intervention for DPN remains unclear. This highlights the need for further research to clarify the therapeutic role of WBV in this patient population.

The growing body of evidence supporting the effectiveness of WBV in improving balance, dual-task performance, and gait in diabetic neuropathy patients suggests that it could be a promising therapeutic approach. The literature emphasizes the necessity for continued research to establish standardized protocols and further explore the physiological mechanisms underlying the potential benefits of WBV in this sensitive population. More well-designed studies are needed to confirm the long-term benefits of WBV training and validate its role in the management of diabetic neuropathy. By incorporating WBV into treatment programs, physiotherapists can provide a more holistic approach to managing diabetic neuropathy, enhancing functional outcomes and potentially improving the quality of life for affected individuals.

This study aims to provide a comprehensive overview of the immediate effects of WBV on balance, dual-task performance, and gait in individuals with diabetic neuropathy. The research will be conducted as a single-blind randomized controlled trial involving 40 participants diagnosed with diabetic peripheral neuropathy, all of whom will be selected voluntarily from a specialized diabetes foot clinic. Participants will be randomly assigned to either the experimental group (receiving WBV training) or the control group, with baseline and post-intervention assessments conducted to measure changes in balance, dual-task performance, and gait. Various tools, including the Timed Up and Go test, the Dual Task Costs formula, and the 1-minute walk test, will be used to assess these parameters. The study will utilize appropriate statistical analyses, including comparisons within and between groups, and will follow ethical guidelines, ensuring informed consent from all participants.

By evaluating these parameters, the study aims to contribute to the understanding of how WBV can improve functional outcomes in individuals with diabetic neuropathy and guide future therapeutic interventions.

03

Conditions studied

  • Diabetus Mellitus
  • Diabetic Foot Ulcer
  • Diabetic Neuropathic Ulcer

Keywords

  • Diabetic Foot
  • Diabetes Mellitus
  • Foot Ulceration
  • Diabetic Neuropathy
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes patients aged 40-75 years,
  • Having a score of 13-29 on the Michigan Questionnaire (intermediate level),
  • Having a Mini Mental Test score of 24 and above,
  • Having an \<8.5%, having controlled blood glucose levels in the last three months,
  • Being able to walk independently
  • Volunteering to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Those with diabetic infected wounds,
  • Those with neurological diseases other than diabetic neuropathy,
  • Those with rheumatoid arthritis, vestibular system disorders, visual
  • Impairments, those with a history of trauma, injury and surgery,
  • Those with knee or hip replacement,
  • Those with a history of epilepsy and cognitive problems.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Control Group

    In the Control Group, balance assessment with the Timed Up and Go Test, evaluation of dual task performance with the Dual Task Cost Gap Formula, and gait assessment with the 1 Minute Walk Test will be performed.

  • Experimental
    Whole Body Vibration Training Group

    For the Whole Body Vibration Training Group, balance, dual task performance and gait will be evaluated. These participants will be evaluated before and after 10 minutes of vibration application.

    Device: The Whole Body Vibration

Interventions

  • DeviceThe Whole Body Vibration

    Whole Body Vibration device may positively affect balance, dual-tasking and gait parameters by increasing the sensory input received under the sole in individuals diagnosed with diabetic foot. In individuals diagnosed with diabetic foot, the sensory/vibration perception threshold of individuals decreases due to the disease, so the balance of individuals is impaired. This may cause these individuals to experience gait disturbances in daily life. There are almost no studies in the literature on the use of whole body vibration for this patient group. This study will discuss the applicability of whole body vibration in the clinic for individuals diagnosed with diabetic foot and that it can be an additional adjunct to treatment.

06

What researchers measure

Primary outcomes

  1. Balance Performance

    Change in balance performance assessed using the Timed Up and Go (TUG) test. The test measures the time taken (in seconds) to rise from a chair, walk 3 meters, turn, and return to sit. Lower times indicate better balance and functional mobility.

    Time frame: For the control group the test will be administered once at baseline and 10 minute later on the same day . In the vibration training group, it will be administered at Baseline (Before WBV) and Immediately After WBV (within 5 minutes).

  2. Gait Performance

    Change in walking capacity measured by the 1-Minute Walk Test. Total distance walked (in meters) is recorded, with greater distances indicating better walking endurance and gait function.

    Time frame: For the control group (one-time assessment at baseline and 10 minutes later), For the WBV Training Group Baseline (Pre-WBV) and Immediately Post-WBV

Secondary outcomes

  1. Functional Mobility (Timed Up and Go Test - TUG)

    Change in functional mobility and dynamic balance measured by the Timed Up and Go (TUG) test. The outcome is the time taken (in seconds) to complete the test. A shorter time after WBV indicates improved mobility and balance.

    Time frame: Start (Before WBV) and Immediately After WBV (within 10 minutes)

  2. Cognitive-Motor Performance (Dual-Task Timed Up and Go Test - DT-TUG)

    Change in cognitive-motor performance measured by the Dual-Task Timed Up and Go (DT-TUG) test. Performance is evaluated through the dual-task gap formula, reflecting the percentage increase in TUG time during the cognitive task. A reduced dual-task gap post-WBV suggests better cognitive-motor integration.

    Time frame: Start (Before WBV) and Immediately After WBV (within 5 minutes)

  3. Walking Capacity (1-Minute Walk Test)

    Change in walking distance measured by the 1-Minute Walk Test. The total distance walked (in meters) reflects gait capacity, endurance, and speed. An increased distance after WBV indicates enhanced walking performance.

    Time frame: Start (Before WBV) and Immediately After WBV (within 5 minutes)

Other outcomes

  1. Patient Demographics and Clinical Characteristics

    Other pre-specified outcomes include patient demographics and clinical characteristics, such as age, weight, gender, duration of diabetes diagnosis, and insulin use, to explore their potential influence on functional outcomes. Glycemic control markers, including the most recent blood glucose value and HbA1c percentage, will be recorded to assess metabolic status. Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE), while peripheral neuropathy severity will be determined through the Michigan Neuropathy Screening Instrument (MNSI) and clinical staging of diabetic neuropathy. Additionally, the use of assistive devices, such as walking aids or orthotics, will be noted, as these factors may influence balance, gait, and dual-task performance. Collectively, these measures provide a comprehensive clinical context to better understand the factors that may modulate the effects of whole-body vibration therapy.

    Time frame: In the study group, the whole body vibration device will be applied by vibrating under the floor at baseline and after 10 minutes in the same day.

  2. Dual-Task Performance

    Change in cognitive-motor function measured using the Dual-Task Timed Up and Go (DT-TUG) test. The dual-task gap formula is applied to calculate the percentage difference between single-task and dual-task states, reflecting the cognitive load's impact on mobility.

    Time frame: For the control group the test will be administered baseline and 15 minutes later in the same day. In the vibration training group, it will be administered at Baseline (Before WBV) and Immediately After WBV (within 5 minutes).

07

Study locations

1 site
  • Gülhane Eğitim ve Araştırma Hastanesi
    Ankara, 06300, Turkey
08

References and documents

Publications

  • Sohrabzadeh E, Kalantari KK, Naimi SS, Daryabor A, Akbari NJ. The immediate effect of a single whole-body vibration session on balance, skin sensation, and pain in patients with type 2 diabetic neuropathy. J Diabetes Metab Disord. 2021 Nov 25;21(1):43-49. doi: 10.1007/s40200-021-00933-w. eCollection 2022 Jun. PubMed 35673453 ↗
  • Jamal A, Ahmad I, Ahamed N, Azharuddin M, Alam F, Hussain ME. Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial. J Diabetes Metab Disord. 2019 Dec 21;19(1):61-69. doi: 10.1007/s40200-019-00476-1. eCollection 2020 Jun. PubMed 32550157 ↗

Individual participant data

Plan to share: No — There is a clause in our consent form about the use of the information for other studies. This is something that is emphasized by our university. Therefore, in order to protect patient rights, it is not possible to share information without patient consent.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Feb 2026, 10 months later.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 10 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 17, 2025
StartEst.
Apr 20, 2025
Primary completionEst.
Feb 20, 2026
CompletionEst.
Feb 20, 2026
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06878651
Collaborators
Gulhane Training and Research Hospital, Gulhane School of Medicine
Responsible party
Tezel Yıldırım Şahan (Associate Professor, Hacettepe University) — Principal investigator
First posted
Mar 17, 2025
Start date
Apr 20, 2025 (estimated)
Primary completion
Feb 20, 2026 (estimated)
Completion
Feb 20, 2026 (estimated)
Last update
Mar 17, 2025

Study contacts

Tezel Şahan
Contact
tezelyildirim.sahan@sbu.edu.tr
+90 ext. 5056615279
Dilek N Kara
Contact
pt.dileknurkara@gmail.com
+90 ext. 5447361583
Tezel Şahan
study director · Gülhane Sağlık Bilimleri Üniversitesi
Dilek N Kara
principal investigator · Bağlı Olmayan
Kerim B Profesör Doktor
study chair · Gulhane Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion